These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 17941755)

  • 1. Bioequivalence study of two nevirapine tablet formulations in human-immunodeficiency-virus-infected patients.
    Tarinas A; Tápanes RD; González D; Ferrer G; Abreu D; Pérez J
    Farm Hosp; 2007; 31(3):165-8. PubMed ID: 17941755
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nevirapine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study.
    Laurito TL; Santagada V; Caliendo G; Oliveira CH; Barrientos-Astigarraga RE; De Nucci G
    J Mass Spectrom; 2002 Apr; 37(4):434-41. PubMed ID: 11948850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combined-formulation tablet of lamivudine/nevirapine/stavudine: bioequivalence compared with concurrent administration of lamivudine, nevirapine, and stavudine in healthy Indian subjects.
    Narang VS; Lulla A; Malhotra G; Purandare S
    J Clin Pharmacol; 2005 Mar; 45(3):265-74. PubMed ID: 15703362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nevirapine/lamivudine/stavudine as a combined-formulation tablet: bioequivalence study compared with each component administered concurrently under fasting condition.
    Monif T; Tippabhotla SK; Garg M; Singla AK; Vijan T
    Int J Clin Pharmacol Ther; 2006 Jun; 44(6):276-83. PubMed ID: 16800100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single-dose, randomized, open-label, two-period crossover bioequivalence study of a fixed-dose pediatric combination of lamivudine 40-mg, nevirapine 70-mg, and stavudine 10-mg tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Rao Thudi N; Koundinya Tippabhotla S; Khuroo A; Marwah A; Kumar Shrivastav V; Tandon M; Raghuvanshi R; Biswal S
    Clin Ther; 2007 Dec; 29(12):2677-84. PubMed ID: 18201583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic profiling and bioequivalence assessment of two marketed brands of nevirapine tablets in healthy Indian volunteers.
    Narang VS; Lulla A; Malhotra G; Purandare S
    Arzneimittelforschung; 2005; 55(10):598-603. PubMed ID: 16294506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.
    Vezina HE; Henry K; Ravindran GD; Kurpad AV; Raj TD; Fox K; Weller D; Brundage RC; Cavert W; Balfour HH
    J Acquir Immune Defic Syndr; 2006 Feb; 41(2):131-6. PubMed ID: 16394842
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
    Byakika-Tusiime J; Chinn LW; Oyugi JH; Obua C; Bangsberg DR; Kroetz DL
    PLoS One; 2008; 3(12):e3981. PubMed ID: 19096711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of extended-release nevirapine 400 and 300 mg in HIV-1: a multicenter, open-label study.
    Battegay M; Arasteh K; Plettenberg A; Bogner JR; Livrozet JM; Witt MD; Mossdorf E; Yong CL; Zhang W; Macha S; Berger F; Stern J; Robinson P; Quinson AM
    Clin Ther; 2011 Sep; 33(9):1308-20. PubMed ID: 21872931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
    Chokephaibulkit K; Cressey TR; Capparelli E; Sirisanthana V; Muresan P; Hongsiriwon S; Ngampiyaskul C; Limwongse C; Wittawatmongkol O; Aurpibul L; Kabat B; Toye M; Smith ME; Eksaengsri A; McIntosh K; Yogev R;
    Antivir Ther; 2011; 16(8):1287-95. PubMed ID: 22155910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study.
    Dos Reis Serra CH; Mori Koono EE; Kano EK; Schramm SG; Armando YP; Porta V
    Clin Ther; 2008 May; 30(5):902-8. PubMed ID: 18555936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A single-dose, randomized, open-label, two-period crossover bioequivalence study comparing a fixed-dose pediatric combination of lamivudine and stavudine tablet for oral suspension with individual liquid formulations in healthy adult male volunteers.
    Monif T; Reyar S; Tiwari HK; Tippabhotla SK; Khuroo A; Thudi NR; Ahmed S; Raghuvanshi R
    Arzneimittelforschung; 2009; 59(2):104-8. PubMed ID: 19338141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and bioequivalence of two formulations of rebamipide 100-mg tablets: a randomized, single-dose, two-period, two-sequence crossover study in healthy Korean male volunteers.
    Cho HY; Yoon H; Park GK; Lee YB
    Clin Ther; 2009 Nov; 31(11):2712-21. PubMed ID: 20110013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bioavailability and bioequivalence of a darunavir 800-mg tablet formulation compared with the 400-mg tablet formulation.
    Kakuda TN; Leopold L; Timmers M; Van De Casteele T; Hillewaert V; Tomaka FL; Hoetelmans RM
    Int J Clin Pharmacol Ther; 2014 Sep; 52(9):805-16. PubMed ID: 25109510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioequivalence of a single 10-mg dose of finasteride 5-mg oral disintegrating tablets and standard tablets in healthy adult male Han Chinese volunteers: a randomized sequence, open-label, two-way crossover study.
    Chen L; Jiang X; Huang L; Lan K; Wang H; Hu L; Ren J; Li X; Zou Q
    Clin Ther; 2009 Oct; 31(10):2242-8. PubMed ID: 19922895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
    Kappelhoff BS; Huitema AD; van Leth F; Robinson PA; MacGregor TR; Lange JM; Beijnen JH;
    HIV Clin Trials; 2005; 6(5):254-61. PubMed ID: 16306032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A single-dose, randomized, two-way crossover study comparing two olanzapine tablet products in healthy adult male volunteers under fasting conditions.
    Elshafeey AH; Elsherbiny MA; Fathallah MM
    Clin Ther; 2009 Mar; 31(3):600-8. PubMed ID: 19393850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Wit FW; Lange JM; Danner SA; Foudraine NA; Kwakkelstein MO; Reiss P; Beijnen JH; Hoetelmans RM
    AIDS; 2000 May; 14(8):F77-82. PubMed ID: 10853971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of two lamivudine tablet formulations.
    Santos-Magalhães NS; Pontes A; Cavalcante RM; Costa RM; Rangel FA; Guimarães MI; de Carvalho JN; de Souza SD; de Oliveira HM; Esteves IL; Ramalho MS; Vieira SL; Alves AJ
    Arzneimittelforschung; 2001; 51(4):310-4. PubMed ID: 11367872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy.
    Stephan C; León W
    HIV Med; 2014 Feb; 15(2):124-8. PubMed ID: 24112515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.